BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34693451)

  • 21. Continuous exposure of non-small cell lung cancer cells with wild-type EGFR to an inhibitor of EGFR tyrosine kinase induces chemoresistance by activating STAT3.
    Tang J; Guo F; Du Y; Liu X; Qin Q; Liu X; Yin T; Jiang L; Wang Y
    Int J Oncol; 2015 May; 46(5):2083-95. PubMed ID: 25695284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glaucocalyxin A-induced oxidative stress inhibits the activation of STAT3 signaling pathway and suppresses osteosarcoma progression in vitro and in vivo.
    Mao M; Zhang T; Wang Z; Wang H; Xu J; Yin F; Wang G; Sun M; Wang Z; Hua Y; Cai Z
    Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1214-1225. PubMed ID: 30659925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
    Zheng B; Ren T; Huang Y; Guo W
    Biochem Biophys Res Commun; 2018 Jan; 495(2):1695-1701. PubMed ID: 29225166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stattic and metformin inhibit brain tumor initiating cells by reducing STAT3-phosphorylation.
    Leidgens V; Proske J; Rauer L; Moeckel S; Renner K; Bogdahn U; Riemenschneider MJ; Proescholdt M; Vollmann-Zwerenz A; Hau P; Seliger C
    Oncotarget; 2017 Jan; 8(5):8250-8263. PubMed ID: 28030813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. STAT3 inhibitor stattic enhances radiosensitivity in esophageal squamous cell carcinoma.
    Zhang Q; Zhang C; He J; Guo Q; Hu D; Yang X; Wang J; Kang Y; She R; Wang Z; Li D; Huang G; Ma Z; Mao W; Zhou X; Xiao C; Sun X; Ma J
    Tumour Biol; 2015 Mar; 36(3):2135-42. PubMed ID: 25492480
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Norcantharidin inhibits proliferation and promotes apoptosis via c-Met/Akt/mTOR pathway in human osteosarcoma cells.
    Mei L; Sang W; Cui K; Zhang Y; Chen F; Li X
    Cancer Sci; 2019 Feb; 110(2):582-595. PubMed ID: 30520540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells.
    Cao W; Liu Y; Zhang R; Zhang B; Wang T; Zhu X; Mei L; Chen H; Zhang H; Ming P; Huang L
    Sci Rep; 2015 Jul; 5():8477. PubMed ID: 26166037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
    Zhang Y; Yao K; Shi C; Jiang Y; Liu K; Zhao S; Chen H; Reddy K; Zhang C; Chang X; Ryu J; Bode AM; Dong Z; Dong Z
    Oncotarget; 2015 Dec; 6(42):44274-88. PubMed ID: 26517520
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kaempferol suppresses glioma progression and synergistically enhances the antitumor activity of gefitinib by inhibiting the EGFR/SRC/STAT3 signaling pathway.
    Zhou J; Liu Y; Chen J; Xiong N; Yi D
    Drug Dev Res; 2023 May; 84(3):592-610. PubMed ID: 36852868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overcoming resistance of targeted EGFR monotherapy by inhibition of STAT3 escape pathway in soft tissue sarcoma.
    Wang X; Goldstein D; Crowe PJ; Yang M; Garrett K; Zeps N; Yang JL
    Oncotarget; 2016 Apr; 7(16):21496-509. PubMed ID: 26909593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liensinine Inhibits Osteosarcoma Growth by ROS-Mediated Suppression of the JAK2/STAT3 Signaling Pathway.
    Jia F; Liu Y; Dou X; Du C; Mao T; Liu X
    Oxid Med Cell Longev; 2022; 2022():8245614. PubMed ID: 35116094
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chloroquine suppresses proliferation and invasion and induces apoptosis of osteosarcoma cells associated with inhibition of phosphorylation of STAT3.
    Chen C; Zhang H; Yu Y; Huang Q; Wang W; Niu J; Lou J; Ren T; Huang Y; Guo W
    Aging (Albany NY); 2021 Jun; 13(13):17901-17913. PubMed ID: 34170850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. (E)-4-(3-(3,5-dimethoxyphenyl)allyl)-2-methoxyphenol inhibits growth of colon tumors in mice.
    Zheng J; Park MH; Son DJ; Choi MG; Choi JS; Nam KT; Kim HD; Rodriguez K; Gann B; Ham YW; Han SB; Hong JT
    Oncotarget; 2015 Dec; 6(39):41929-43. PubMed ID: 26474284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer.
    Wen W; Wu J; Liu L; Tian Y; Buettner R; Hsieh MY; Horne D; Dellinger TH; Han ES; Jove R; Yim JH
    Mol Cancer; 2015 May; 14():100. PubMed ID: 25928246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. STAT3 inhibitory stattic enhances immunogenic cell death induced by chemotherapy in cancer cells.
    Jafari S; Lavasanifar A; Hejazi MS; Maleki-Dizaji N; Mesgari M; Molavi O
    Daru; 2020 Jun; 28(1):159-169. PubMed ID: 31942696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. β-Elemonic acid inhibits the growth of human Osteosarcoma through endoplasmic reticulum (ER) stress-mediated PERK/eIF2α/ATF4/CHOP activation and Wnt/β-catenin signal suppression.
    Zhao A; Zhang Z; Zhou Y; Li X; Li X; Ma B; Zhang Q
    Phytomedicine; 2020 Apr; 69():153183. PubMed ID: 32113150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells.
    Moon SY; Lee H; Kim S; Hong JH; Chun SH; Lee HY; Kang K; Kim HS; Won HS; Ko YH
    BMC Cancer; 2021 Aug; 21(1):931. PubMed ID: 34407787
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cinobufagin Suppresses The Characteristics Of Osteosarcoma Cancer Cells By Inhibiting The IL-6-OPN-STAT3 Pathway.
    Zhang C; Ma K; Li WY
    Drug Des Devel Ther; 2019; 13():4075-4090. PubMed ID: 31824138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.
    Pan L; Chen X; Fu S; Yu W; Li C; Wang T; Lo HW; Lin J
    Breast Cancer Res Treat; 2020 May; 181(1):31-41. PubMed ID: 32240456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
    Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
    BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.